NEMAURA MEDICAL

NASDAQ: NMRD

Better Diagnostics for Life

Corporate Presentation

September 2018

Forward-Looking Statement

This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura's short-term and long-term growth strategies, can sometimes be identified by use of terms such as "intend," "expect," "plan," "estimate," "future," "strive," and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. These risks are discussed in Nemaura's filings with the Securities and Exchange Commission (the "Commission"), including the risks identified under the section captioned "Risk Factors" in Nemaura's Quarterly Report on Form 10-Q filed with the Commission on February 09, 2018 and in Nemaura's Registration Statement on Form S-3 filed with the Commission on March 18, 2016. Nemaura disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

sugarBEAT® Core Proposition

Bringing glucose trending to non insulin using diabetics

(Total Addressable Market $31.4Bn)

Expanding glucose monitoring to all insulin users

(Total Addressable Market $38.0Bn)

Combined TAM $69.4Bn[1]



[1]PiperJaffray Company Note DXCM Sep 5 2018

sugarBEAT® Continuous Glucose Monitoring (CGM)[1]

A large and growing opportunity

- CGM adoption rates are minimal yet growing fast



- U.S. is largest market with usage increasing by 117% to 2.6% of total diagnosed diabetic pop. of 24.6M (estimated 630k users in 2018 v 290k users in 2017)

- Of 630k CGM users, 478k are Type I insulin users and 151k are Type II insulin users

[1]PiperJaffray Company Note DXCM Sep 5 2018

sugarBEAT® Continuous Glucose Monitoring (CGM) TAM [1]

A large and growing opportunity

- Global Total Addressable Market for CGM worth $82Bn per annum:



- Type II Insulin & Non-Insulin users are core sugarBEAT® markets with TAM of $69.4B
- Above excludes pre-diabetics population, which is circa 3 times as large

[1] PiperJaffray Company Note DXCM Sep 5 2018

sugarBEAT® Diabetic User Segmentation

A large and growing opportunity

- Insulin users (20% of diabetics) use finger stick / CGM to manage glucose levels
- Non-insulin users (80% of diabetics) use HbA1c to manage glucose levels
- Pre-diabetics (x3 as large), use HbA1c to manage glucose levels
- Current CGM products cater primarily for insulin users
- 80% of diabetics therefore tend not to use finger sticks daily. They rely on HbA1c
- Invasive nature of current CGM may not appeal to those who do not finger stick

[1]PiperJaffray Company Note DXCM Sep 5 2018

sugarBEAT® Core Strengths

- SugarBEAT® has three core strengths:
- (1) Non-invasive (sensor sits on top of the skin without any insertion into skin)
- (2) Affordable (~$2 anticipated daily retail price)
- (3) Flexible (can be worn on non-consecutive days given 24 hour patch wear time)
- These three factors key to achieving adoption by non insulin using diabetics as well as significant proportion of insulin using diabetics

sugarBEAT® Core Components

- SugarBEAT® consists of three components:
- (1) Daily-disposable adhesive skin-patch (up to 24 hour wear time with 30-60 minute warm up)
- (2) a rechargeable transmitter (integrated into skin-patch)
- (3) an app displaying glucose readings (at regular five minute intervals)
- SugarBEAT® intended for adjunctive use



sugarBEAT® Two Core Applications (1)

- SugarBEAT® as a Glucose **Monitoring** Product.
- Target insulin users who typically require 6-8 daily finger stick readings
- SugarBEAT® requires finger stick calibration each time new patch applied
- SugarBEAT® requires confirmatory finger stick reading for insulin dosage decisions
- Primary purpose to help monitor fluctuations in glucose levels and provide adjunctive support for insulin dosage

sugarBEAT® Two Core Applications (2)

- SugarBEAT ® as a Glucose **Trending** Product.
- Target Audience non insulin using persons with diabetes and pre-diabetics who typically rely on HbA1c readings and rarely use finger stick readings
- Does not require finger stick calibration each time new patch applied hence fully non-invasive
- Primary purpose to provide more meaningful information as to causality between lifestyle factors and glucose fluctuations (Ambulatory Glucose Profile) as compared to HbA1c readings

Market Segmentation

Patient Population Breakdown

Target Patient Group	Competitor Market Penetration	Projected sugarBEAT Market Penetration
Type 1 Insulin-Dependent (~5% of diabetics) [2]	Dexcom: 270K patients after 8 years[1]	Minimal (target those refusing to use existing CGM due to long wear time)
Type 2 Insulin-Dependent (~15% of diabetics) [2]	Abbott Libre: 800K patients after 4 years[3]	Up to 10% within 5 years (SugarBEAT® more affordable and flexible)
Type 2 Non-Insulin-Dependent (~80% of diabetics) [2]	Negligible	Up to 15% within 5 years (SugarBEAT® non-invasive)

Sources: [1] JPMorgan Chase & Co., "Libre Launch Off to a Fast Start: What It Means for ABT & DXCM," February 26, 2018, available from Nasdaq IR Insight.
2. Nemaura estimate 3. https://view.pagetiger.com/desang-magazine

sugarBEAT® Market Rationale

Target Patient Population

Target Patient Group	Rationale for Market Penetration
Type 1 Insulin Dependent	• Patients already tolerate multiple daily invasive procedures • Competitors CGM products do not require finger prick calibration • Patients at risk of hypo hence may prefer therapeutic CGM for insulin dosage • Patients have highest adoption rate of existing CGM products and insulin pumps
Type 2 Insulin Dependent (Reimbursed basis)	• Target those patients not using CGM and insulin pumps • Finger stick reduction (not replacement) for adjunctive use • Key attraction flexibility and cost • Patients may prefer intermittent patch wear (on non-consecutive day basis)
Type 2 Non-Insulin Dependent (Self-pay basis)	• Patients currently rely on finger stick, with CGM use negligible • Finger stick reduction (not replacement) • Key attraction non-invasiveness given they do not inject insulin • Patients likely to prefer intermittent patch wear (lower ratio than insulin users)

sugarBEAT® Upcoming Milestones

Non-invasive, Flexible and Affordable

- CE Mark approval expected in coming weeks
- SugarBEAT® commercial launch expected Q4 2018 in UK, with major European countries following in H1 2019
- FDA 525 patient day clinical program expected to complete in Q1 2019, with FDA submission and data published in early Q2 2019

sugarBEAT® Completed Milestones

Non-invasive, Flexible and Affordable

- Published sugarBEAT® data sets on interim FDA clinical trials in Q3 2018
- SugarBEAT® completed 525 patient day (75 patients x 7 days) European Trial in Q4 2017
- CE Mark granted Q1 2016 on predecessor version (wrist-watch format)

Interim Comparative MARD for FDA **home-study** phase as Primary Accuracy Metric

Device	Number of subjects	Paired Data Points with BGM	Nominal MARD	Reference BGM
Senseonics Eversense*	23	829	14.80%	Nova Biomedical StatStrip Xpress
Dexcom G5*	23	829	16.30%	Nova Biomedical StatStrip Xpress
Abbott Libre Pro*	23	829	18.00%	Nova Biomedical StatStrip Xpress
sugarBEAT	36	126	16.30%	Abbott Freestyle Optimum neo

Full dataset available to view at http://nemauramedical.com/publications/

Note 1: Senseonics, Dexcom G5 and sugarBEAT = 2 point finger prick calibration

*http://www.diabetesincontrol.com/accuracy-comparison-of-the-dexcom-g5-abbott-freestyle-libre-pro-and-senseonics-eversense/

Interim Comparative MARD for FDA **In-Clinic** phase as Primary Accuracy Metric

Dexcom G5*	no. of calibrations not known	Overall MARD (20%/20mg/dL)	9.00
		% Data	94.00
sugarBEAT	1-point calibraiton	Overall MARD (20%/20mg/dL)	8.77
		% Data	62.61
	2-point calibraiton	Overall MARD (20%/20mg/dL)	7.97
		% Data	74.00
	1-point calibraiton	Overall MARD (30%/30mg/dL)	12.19
		% Data	79.91
	2-point calibraiton	Overall MARD (30%/30mg/dL)	10.65
		% Data	88.57

Full dataset available to view at http://nemauramedical.com/publications/

* https://dexcom.gcs-web.com/static-files/0a1461dd-e75a-4759-9ddf-50b834756bdd

sugarBEAT® Clinical Data

Q4 2017 European Clinical Data Summary, Type 1 and 2 Diabetics

Study Criteria and Performance Metrics

The following criteria have been employed to measure the performance of the sugarBEAT® device:

Parameter	Study 1
Reference Device	Yellow Springs Instrument (YSI) glucose analyser equivalent
Patient Population	Type I and Type II: 75 patients, 7 days each [of which 3 days in-clinic with venous catheter]
Total Duration of in-clinic portion of Study	14 hours, including 2 hours warm-up x 3 days
Device readings per 12 hour study	1 per 5 minutes = 168 per 14 hours
Venous Catheter blood draw	Once per 15 minutes
Total Paired Data Points	>3,500 for a 25 patient cohort
Interim Precision	1.07
Overall Mean Absolute Relative Difference (MARD)	<14%
Clinical Utility of Data	Clark Error Plot – >70% in Zone A are currently being evaluated

sugarBEAT® Market Launch Strategy

Territory (in order of launch)	Partner	Launch Plan
UK	DBJ Jersey – Supply agreement	Direct to Market by DBJ, Reimbursement/Drug Tariff Listing
EU	DBJ Jersey 50:50 JV	Sub-license to Multinationals
GCC	TP MENA – non-binding letter of intent (Qatar via Al Danah Medical Co)	Direct to Market and Government Subsidized
Australia	Device Technologies – non-binding letter of intent	Direct to Market and Government Subsidized
HK	TBD	TBD
USA	TBD	In Discussions with 2 of the Top 5 Companies in the Diabetes Field

Active R&D Pipeline

Product	Key Features	Market
SugarBEAT Generation II *	• Include Pediatric Cover • Improved Accuracy (MARD) • Longer patch wear time (72 hours)	Diabetics + Pre-Diabetics
In-Clinic variant of SugarBEAT **	• Provide glucose monitoring for immobile patients • Minimal warm up period • Wired device format compatible with hospital monitoring systems	Hospital Critical Care

- Platform technology can be adapted to apply to broad range of analytes beyond glucose

* 18-24 month development timeframe

** 36 month development timeframe

Management

Dr. Dewan Fazlul Hoque Chowdhury
Chief Executive Officer

- Over 18 years' experience in the pharmaceutical and medical device industry and holder of over 50 patents across more than 15 patent families
- 2009-Present: President, Chief Executive Officer and Board Director in charge of research and development of core technologies, product development, innovation and commercialization; coordinates and oversees legal compliance; development of the company mission; policy and planning
- 2005- 2009: founder and CEO of Microneedle Technologies and Nemaura Pharma Limited; developed and launched a microneedle device used in skin clinics; responsible for negotiating licensing deals for a transdermal patch to treat Alzheimer's disease currently under FDA review
- MSc in Microsystem and nanotechnology, from Cranfield University and PhD in Nanomedicine from Oxford University

Iain Anderson
Chief Financial Officer

- Chartered Certified Accountant since 1992
- Over twenty years' experience with US-owned businesses, including subsidiaries of Hitachi, TriMas Corporation, Precision Castparts Corporation and Hospira Inc.
- Qualified whilst working for the Big Four UK practice of Touche Ross (now Deloitte)
- Joined Nemaura Medical Inc in August 2016
- Gained an MBA from Loughborough University in 1999

Bashir Timol
Chief Business Officer

- Co-founded, managed and funded several life sciences and medical device companies
- Led investment consortium that provided first two rounds of funding for Nemaura Medical
- 2013-Present: Board Member NMRD
- April 18 – Present: CBO NMRD
- 2007-Present: Investor and NED at Nemaura Pharma Ltd, which offers precise, easy to use and minimally invasive skin based drug delivery technologies
- 2016 -Present: Investor and NED at Diagnostax Limited, which helps accountants provide better tax advice to more of their clients through cloud based software
- Bachelor degree in Economics from the Univ of Central Lancashire, UK.

Market Data

Nemaura Medical Inc.	NASDAQ:NMRD
Fiscal Year:	March
Industry:	Medical Devices
Recent Share Price (Sep 18 2018)	$3.18
Market Cap	$651.9M
Shares Outstanding:	205.0 million
Warrants Outstanding:	10.0 million (strike price of $0.50)
Equity Float:	59.0 million
Insider Ownership:	71%
50 Day Average Daily Volume:	166,972
Balance Sheet (30 June 2018)	$4.94M